The Royal Orthopaedic Hospital Oncology Service, Royal Orthopaedic Hospital, Birmingham, UK.
Musculoskeletal Tumor Service, Karolinska University Hospital, Stockholm, Sweden.
J Surg Oncol. 2022 Sep;126(4):787-792. doi: 10.1002/jso.26926. Epub 2022 May 18.
Treatment of high-grade osteosarcoma (OS) relies on a combination of systemic chemotherapy and radical surgical excision of the tumor. Little is known on what happens in case of an irrefutably inadequate (intralesional) margin. We aimed to describe the outcome of patients with high-grade OSs of the trunk and the extremities where planned wide resection resulted in an intralesional margin.
A retrospective study from the Scandinavian Sarcoma Group registry and the Royal Orthopaedic Hospital databases including data from 53 patients surgically treated between the years 1990 and 2017.
Local recurrence was observed in 13/53 patients. All patients with local recurrence where the neoadjuvant chemotherapy response could be retrieved (n = 9) were shown to be poor responders. None of the patients with good response to chemotherapy relapsed. Postoperative radiotherapy was not associated with improved local control of the disease. Re-excision surgery was performed in only seven patients, and two of them had tumor relapse.
Good response to chemotherapy salvages the outcome of surgical excision with a poor margin in patients with high-grade OSs and a watchful waiting strategy may be justified in these cases. Poor responders have a higher recurrence risk and their approach should be individualized.
高级骨肉瘤(OS)的治疗依赖于全身化疗和肿瘤的根治性手术切除的联合。对于明确不足(腔内)切缘的情况下会发生什么,知之甚少。我们旨在描述躯干和四肢高级 OS 患者的结果,这些患者计划进行广泛切除,导致腔内切缘。
这是一项来自斯堪的纳维亚肉瘤组登记处和皇家骨科医院数据库的回顾性研究,包括 1990 年至 2017 年间接受手术治疗的 53 名患者的数据。
在 53 名患者中,有 13 名出现局部复发。所有可检索新辅助化疗反应的局部复发患者(n=9)均为不良反应者。无良好化疗反应者复发。术后放疗与疾病局部控制的改善无关。仅对 7 名患者进行了再次切除术,其中 2 名患者肿瘤复发。
在高级骨肉瘤患者中,对化疗的良好反应挽救了手术切除的结果,在这些情况下,密切观察等待策略可能是合理的。不良反应者复发风险更高,其方法应个体化。